"Adjuvants, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Descriptor ID |
D000276
|
MeSH Number(s) |
D27.505.696.477.067
|
Concept/Terms |
Adjuvants, Immunologic- Adjuvants, Immunologic
- Immunostimulants
- Adjuvant, Immunologic
- Immunologic Adjuvant
- Immunological Adjuvant
- Adjuvant, Immunological
- Immunoactivators
- Immunoadjuvants
- Immunologic Adjuvants
- Immunopotentiators
- Adjuvants, Immunological
- Immunological Adjuvants
|
Below are MeSH descriptors whose meaning is more general than "Adjuvants, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Adjuvants, Immunologic".
This graph shows the total number of publications written about "Adjuvants, Immunologic" by people in this website by year, and whether "Adjuvants, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 1 | 1 | 2 |
2005 | 0 | 1 | 1 |
2008 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles.
-
TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. J Cancer Res Clin Oncol. 2023 Feb; 149(2):833-840.
-
Infection of myeloid dendritic cells with Listeria monocytogenes leads to the suppression of T cell function by multiple inhibitory mechanisms. J Immunol. 2008 Oct 01; 181(7):4976-88.
-
CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood. 2006 Apr 01; 107(7):2786-9.
-
Combined activation of innate and T cell immunity for recognizing immunomodulatory properties of therapeutic agents. J Leukoc Biol. 2004 Apr; 75(4):624-30.
-
DCs in lymphoma--biology and therapeutic aspects. Cytotherapy. 2004; 6(2):138-47.